A Nationwide Observational Study of Ponatinib in CML Patients Outside of Clinical Trials- The Israeli Experience

The oral tyrosine kinase inhibitor (TKI) ponatinib is indicated for T315I positive CML patients and for patients who cannot be prescribed any other TKI. Currently, there is little real-life information regarding the use of ponatinib outside of clinical trials.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Irina Amiati, Adi Shacham-Abulafia, Roy Ratzon, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Hellmann, Liat Shargian, Anna Gourevietch, Evgeni Chubar, Uri Rozovski Source Type: research